Buy ESPEROCT 2000 UNIT ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, B-DOMAIN TRUNCATED), PEGYLATED

Esperoct 2000 Unit is a recombinant antihemophilic factor VIII used for managing hemophilia A. This powder for solution is designed for intravenous administration and is manufactured by Novo Nordisk Canada Inc.

Strength

2000 UNIT

Manufacturer / TM Owner

NOVO NORDISK CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Esperoct 2000 Unit is primarily used to control and prevent bleeding episodes in patients with hemophilia A, a genetic disorder that impairs blood clotting. It works by replacing the missing clotting factor VIII, which is essential for normal blood coagulation. This medication is often used in situations where bleeding control is critical, such as during surgery or after an injury.

Side Effects

When administered as directed, Esperoct 2000 Unit helps to restore normal clotting function, reducing the risk of prolonged bleeding. Patients may experience improved clotting times and fewer bleeding episodes. However, individual responses can vary, and it is important to follow medical guidance for optimal results.

Precautions & Warnings

Esperoct 2000 Unit should be handled with care and stored according to the manufacturer's instructions to maintain its efficacy. Patients should be monitored for any signs of allergic reactions or adverse effects. It is crucial to use this medication under the supervision of a healthcare professional.

Avoid Interactions

Esperoct 2000 Unit may interact with other medications or substances, so it is important to inform your healthcare provider about all medications you are taking. Certain medications, such as those that affect blood clotting, may require careful monitoring when used concurrently with Esperoct.

References

Frequently Asked Questions

Esperoct 2000 Unit is used to manage and prevent bleeding episodes in patients with hemophilia A by replacing the missing clotting factor VIII.

Esperoct 2000 Unit is administered intravenously as a powder for solution, typically under the supervision of a healthcare professional.

Common effects include improved clotting function and reduced bleeding episodes, though individual responses may vary.

Yes, it is important to handle and store Esperoct 2000 Unit properly and to monitor for any signs of allergic reactions or adverse effects.

Yes, Esperoct 2000 Unit may interact with other medications, particularly those that affect blood clotting, so it is important to inform your healthcare provider about all medications you are taking.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.